Dare Bioscience (DARE) Reports FY17 EPS Loss of $3.47

Note: EPS may not be comparable

Dare Bioscience (NASDAQ: DARE) reported Q4 EPS of ($3.47).

The net loss for the full year ended December 31, 2017 was $11,527,721 (or $3.57 per share), compared to the net loss of $672,687 (or $0.81 per share) for the full year ended December 31, 2016. The 2017 financial statements represent Daré’s operations as a public company following the completion of a stock purchase transaction on July 19, 2017. The financial statements presented for 2016 represent Daré operations when the Company was private, making a comparison between periods difficult.

“2017 was a year of transformative growth for Daré Bioscience as we established a strong foundation for our goal of building a preeminent company in women’s reproductive health. We expect that our year end cash balance of approximately $7.56 million will enable us to fully fund an important clinical study evaluating Ovaprene, which, if approved, has the potential to fill a significant gap in the marketplace as the first woman-initiated non-hormonal contraceptive providing protection over the course of several weeks,” stated Sabrina Martucci Johnson, Chief Executive Officer at Daré. “Additionally, in the first quarter of 2018, we announced the addition of Topical Sildenafil, a product with the potential to be the first product approved for Female Sexual Arousal Disorder, and raised approximately $10.4 million in net proceeds through the sale of equity securities to continue its development into Phase 2b. Each of our two lead development programs has the potential to deliver a first-in-category product addressing unmet need in women’s reproductive health, and, together with our pre-clinical injectable contraceptive program, constitute a differentiated portfolio that we believe is well positioned to drive significant value in both the short and long term.”

For earnings history and earnings-related data on Dare Bioscience (DARE) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Unilever PLC (UL) Q1 Revenue Misses Estimates
• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises